As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of In8bio, Inc. The largest reported stake is Lytton Laurence W's, at 9.99%. 13 filings are on record since July 29, 2025 (Schedule 13G/A, August 13, 2026).
Sell to companies like In8bio, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Lytton Laurence W · Sole voting: 0 · Shared voting: 1,056,513 · Sole dispositive: 0 · Shared dispositive: 1,056,513 · SCHEDULE 13G/A, 2026-08-13
- · Holder: Emily Fairbairn · Percent: 2.2% · SCHEDULE 13D/A
- · Holder: Lytton Laurence W · Percent: 9.99% · SCHEDULE 13G
- · Holder: Alyeska Investment Group, L.P. · Percent: 9.9% · SCHEDULE 13G
- · Holder: Franklin Resources, Inc. · Percent: 9.4% · SCHEDULE 13G
In8bio, Inc. has 13 Schedule 13D or 13G filings on record since 2025-07-29. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 9.99% | 1,056,513 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 | |
| Alyeska Investment Group, L.P. | 9.9% | 966,381 | SCHEDULE 13G, 2026-02-17 | 2025-12-31 |
| Stonepine Capital Management, LLC | 9.9% | 1,007,990 | SCHEDULE 13G, 2025-12-22 | 2025-12-19 |
| Franklin Resources, Inc. | 9.4% | 914,531 | SCHEDULE 13G, 2026-01-29 | 2025-12-31 |
| 683 Capital Management, LLC | 7.86% | 770,445 | SCHEDULE 13G, 2025-12-30 | 2025-12-22 |
| 4.4% | 149,895 | SCHEDULE 13G/A, 2025-07-29 | 2025-06-30 | |
| BIOS Fund II, LP | 4% | 19,147 | SCHEDULE 13D/A, 2025-12-29 | 2025-12-22 |
| 3.7% | 151,223 | SCHEDULE 13G/A, 2025-08-13 | 2025-06-30 | |
| Transcend Partners Opportunity Fund LLC | 2.6% | 107,416 | SCHEDULE 13G/A, 2025-08-13 | 2025-06-30 |
| 2.2% | 215,431 | SCHEDULE 13D/A, 2026-05-29 | 2026-05-27 |
Holding shares or following this stake? See who's behind In8bio, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on In8bio, Inc. and the records around it.
In8bio, Inc. elsewhere on the record
- Form D filing Dec 2025
- Who owns it
Companies that share a holder
- 683 Capital Management, LLC also filed stake reports on 10 other companies: Perceptive Capital Solutions Corp (Aug 2026), Gossamer Bio, Inc. (Jun 2026), FRACTYL HEALTH, INC. (May 2026)
- Stonepine Capital Management, LLC also filed stake reports on 17 other companies: Femasys Inc (Aug 2026), Edesa Biotech, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- LYTTON LAURENCE W also filed stake reports on 28 other companies: Retension Pharmaceuticals, Inc. (Oct 2026), Rank One Computing Corp (Aug 2026), MDxHealth SA (Aug 2026)
Watch In8bio, Inc.
Get an email when In8bio, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on In8bio, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on In8bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on In8bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Lytton Laurence W | 0 | 1,056,513 | 0 | 1,056,513 | SCHEDULE 13G/A, 2026-08-13 |
| Lytton-Kambara Foundation | 0 | 1,056,513 | 0 | 1,056,513 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies In8bio, Inc. by CUSIP 45674E208 and gives its principal executive office as EMPIRE STATE BUILDING, 350 5TH AVENUE, SUITE 5330, NEW YORK, NY 10118 (SCHEDULE 13G/A, 2026-08-13).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-29 | Orin Hirschman | 4.4% | SCHEDULE 13G/A |
| 2025-08-13 | William Tai-Wei Ho | 3.7% | SCHEDULE 13G/A |
| 2025-08-13 | Transcend Partners Opportunity Fund LLC | 2.6% | SCHEDULE 13G/A |
| 2025-08-14 | Alyeska Investment Group, L.P. | 2.58% | SCHEDULE 13G/A |
| 2025-12-22 | Stonepine Capital Management, LLC | 9.9% | SCHEDULE 13G |
| 2025-12-29 | BIOS Fund II, LP | 4% | SCHEDULE 13D/A |
| 2025-12-30 | 683 Capital Management, LLC | 7.86% | SCHEDULE 13G |
| 2026-01-02 | Emily Fairbairn | 7.5% | SCHEDULE 13D |
| 2026-01-29 | Franklin Resources, Inc. | 9.4% | SCHEDULE 13G |
| 2026-02-17 | Alyeska Investment Group, L.P. | 9.9% | SCHEDULE 13G |
| 2026-03-02 | Lytton Laurence W | 9.99% | SCHEDULE 13G |
| 2026-05-29 | Emily Fairbairn | 2.2% | SCHEDULE 13D/A |
| 2026-08-13 | Lytton Laurence W | 9.99% | SCHEDULE 13G/A |
Questions about who owns In8bio, Inc.
Who owns In8bio, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of In8bio, Inc.: Lytton Laurence W (9.99%, Schedule 13G/A, filed 2026-08-13), Alyeska Investment Group, L.P. (9.9%, Schedule 13G, filed 2026-02-17), Stonepine Capital Management, LLC (9.9%, Schedule 13G, filed 2025-12-22), Franklin Resources, Inc. (9.4%, Schedule 13G, filed 2026-01-29) and 683 Capital Management, LLC (7.86%, Schedule 13G, filed 2025-12-30).
Who are the largest shareholders of In8bio, Inc.?
By the share each holder's latest filing reports, the largest holders of In8bio, Inc. on this page are Lytton Laurence W (9.99%), Alyeska Investment Group, L.P. (9.9%) and Stonepine Capital Management, LLC (9.9%).
When did Lytton Laurence W buy into In8bio, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lytton Laurence W on this page is the Schedule 13G, filed 2026-03-02, reporting 9.99%; its latest, Schedule 13G/A filed 2026-08-13, reports 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for In8bio, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| December 30, 2025 | Form D, private offering | $20.12M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for In8bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.